Loading stock data…
$10.61-0.18 (-1.67%)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally.
ImmuCell Corporation in the Healthcare sector is trading at $10.61 with a market capitalization of $89M. The stock is currently near its 52-week high of $12.10, remaining 23.1% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $7.19M↓ | $10.36M↑ | $7.63M↑ | $5.51M↓ | $6.44M |
| Gross Profit | $2.44M↓ | $4.66M↑ | $2.91M↑ | $2.36M↓ | $2.82M |
| Operating Income | $1.93M↓ | $1.97M↑ | -$57,956↓ | $20,075↓ | $569,562 |
| Net Income | $1.83M↓ | $1.94M↑ | -$2.85M↓ | -$139,748↓ | $501,880 |
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Masti...